Actualités réglementaires
3 sept. 2026•1 min de lecture
FDA Approves Apotex CILOSTAZOL (ANDA077030)
FDA has approved Apotex's oral cilostazol tablets (50 mg and 100 mg) under ANDA 077030, adding a generic phosphodiesterase‑3 inhibitor to the market.
Actualités réglementaires
30 août 2026•1 min de lecture
FDA Approves CILOSTAZOL Tablets (ANDA077831)
FDA has approved Chartwell Rx's ANDA077831 for oral CILOSTAZOL tablets in 50 mg and 100 mg strengths, with labeling updates approved in 2016.